90 results
POS AM
PBLA
Panbela Therapeutics, Inc.
29 Mar 24
Prospectus update (post-effective amendment)
5:08pm
to continue to operate our business and complete our clinical development plans.
Future research and development, including clinical trial cost, capital … resources, research and development staff and facilities than we have. In addition, many of our competitors are more experienced in drug discovery
8-K
EX-99.1
PBLA
Panbela Therapeutics, Inc.
26 Mar 24
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
4:12pm
quarter of 2023, compared to $1.7 million in the fourth quarter of 2022.
Research and development expenses were $6.1 million in the fourth quarter … December 31,
Percent
Change
Percent
Change
Operating expenses:
General and administrative
Research and development
Operating loss
Other income
8-K
EX-99.1
iiyouhc
9 Nov 23
Panbela Provides Business Update and Reports Q3 2023 Financial Results
4:10pm
8-K
EX-99.1
7qy1ph4e6rqdcc
10 Aug 23
Panbela Provides Business Update and Reports Q2 2023 Financial Results
4:11pm
424B4
ii39 ylxn9nkhi1f
20 Jun 23
Prospectus supplement with pricing info
5:19pm
8-K
EX-99.1
hyjou7u32 rnuu3ncp
4 May 23
Panbela Provides Business Update and Reports Q1 2023 Financial Results
4:11pm